Search Results 351-360 of 18015 for Alopecia

1. PKCι & mTOR Inhibition With Auranofin+Sirolimus for Squamous Cell Lung Cancer - Mayo Clinic

   Recovered from the toxic effects of radiation treatment before study entry, except for alopecia. Absolute neutrophil count (ANC) ≥ 1500 uL; Platelets (PLT) ...

2. Head and neck cancers - Doctors and departments - Mayo Clinic

   ... Alopecia areata, Melasma. Show more areas of focus for Ashley B. Wentworth, M.D.. Josh P. Wiedermann, M.D.. Otolaryngologist. Rochester ...

3. A Study to Test Long-term Treatment With Brigimadlin in People With Solid Tumours Who Took Part in a Previous Study With This Medicine - Mayo Clinic

   ... alopecia and amenorrhea/menstrual disorders which can be any grade and peripheral neuropathy which must be CTCAE Grade ≤2). Cohort 1 only: 7. Patient is ...

4. Study Of SIM0500 Alone In Participants With Relapsed Or Refractory Multiple Myeloma - Mayo Clinic

   Toxicities from previous anticancer therapies should have resolved to baseline levels or to Grade 1 or less except for alopecia or peripheral neuropathy. 2 ...

5. Phase Ib Study of Axatilimab in Combination with Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Breast Cancer - Mayo Clinic

   ... alopecia, are excluded. * History of allergic reactions attributed to compounds of similar chemical or biologic composition to axatilimab or olaparib ...

6. A Study of Abemaciclib (LY2835219) in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer - Mayo Clinic

   ... alopecia or peripheral neuropathy. Have discontinued all previous therapies for cancer (including chemotherapy, radiotherapy, immunotherapy, and endocrine ...

7. Clinical trials - Oncology (Medical)

   Natural History Evaluation Among Female Breast Cancer Survivors with Endocrine Therapy-Induced Alopecia. Rochester, Minn., Mankato, Minn., Albert Lea, Minn ...

8. Glembatumumab Vedotin in Treating Patients With Metastatic or Locally Recurrent Uveal Melanoma - Mayo Clinic

   All prior treatment-related toxicities must be Common Terminology Criteria for Adverse Events (CTCAE) version (v) 4 grade =< 1 (except alopecia); certain ...

9. Study of AG-270 in Participants With Advanced Solid Tumors or Lymphoma With MTAP Loss - Mayo Clinic

   Residual chronic toxicities of prior therapy ≤ Grade 2 (eg, peripheral neuropathy, residual alopecia) are allowed. Female subjects who are pre-menopausal ...

10. Clinical trials - Oncology (Medical)

    Natural History Evaluation Among Female Breast Cancer Survivors with Endocrine Therapy-Induced Alopecia. Rochester, Minn., Mankato, Minn., Albert Lea, Minn ...